Clinical trial
Safety and Efficacy of Hormone Therapy With Letrozole in Postmenopausal Women…
NCT00330317 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00330317 |
|---|---|
| Title | Safety and Efficacy of Hormone Therapy With Letrozole in Postmenopausal Women With Breast Cancer |
| Official title | Neoadjuvant Hormone Therapy for Postmenopausal Women With HR+ Primary Breast Cancer: A Multi-center Study to Determine the Optimum Length of Treatment With Letrozole on Tumour Regression to Permit Breast Conserving Surgery. |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | letrozole |
| Enrollment | 300 |
| Start date | Feb 1, 2006 |
| Primary completion | Mar 1, 2010 |
| Completion | Nov 16, 2010 |
| First posted | May 26, 2006 |
| Last update posted | Feb 7, 2017 |
| Countries | United Kingdom |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: